{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:01:16Z","timestamp":1772150476557,"version":"3.50.1"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T00:00:00Z","timestamp":1689984000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>A high SUV<jats:sub>max<\/jats:sub> tumor-to-liver ratio (TLR) of <jats:sup>68<\/jats:sup>Ga-DOTATATE can be used to select patients with neuroendocrine tumors (NETs) for peptide receptor radionuclide therapy (PRRT). In addition, an SUV<jats:sub>max<\/jats:sub> TLR \u2265 8.1 is associated with increased progression-free survival in NET patients treated with somatostatin analogs (SSAs). To avoid a theoretical interaction, several guidelines recommend performing PET\/CT just before the monthly administration of long-acting SSAs. We aimed to investigate the effect of SSA on the SUV<jats:sub>max<\/jats:sub> of <jats:sup>68<\/jats:sup>Ga-DOTATATE in patients with NET and to identify independent predictors for high SUV<jats:sub>max<\/jats:sub> TLR.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods<\/jats:title>\n            <jats:p>For this retrospective study, 192 <jats:sup>68<\/jats:sup>Ga-DOTATATE PET\/CT scans of 165 patients without (n = 115) and with (n = 77) SSA (octreotide or lanreotide) in the 3 months before PET\/CT were collected and reviewed. The effect of SSA on SUV<jats:sub>max<\/jats:sub> values was analyzed by a maximum likelihood mixed model.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Patients with SSA had a significantly higher median SUV<jats:sub>max<\/jats:sub> TLR than patients without SSA (4.7 [IQR], 3.1\u20137.7) versus 3.2 [IQR, 2.0\u20135.4]; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001). Multivariable logistic regression analysis showed that SSA use was an independent predictor for SUV<jats:sub>max<\/jats:sub> TLR \u2265 8.1 (odds ratio, 2.91; 95% confidence interval, 1.26\u20136.72; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.012).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Our data suggest that higher SSA concentrations do not have a negative effect on <jats:sup>68<\/jats:sup>Ga-DOTATATE uptake in tumor lesions. In addition, we found that only SSA use was associated with SUV<jats:sub>max<\/jats:sub> TLR \u2265 8.1. Our results are consistent with previously conducted studies and in line with the recently published guideline that suggests that the relatively recent use of SSA does not necessitate any delay in <jats:sup>68<\/jats:sup>Ga-DOTATATE PET\/CT imaging.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000004776","type":"journal-article","created":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T15:00:09Z","timestamp":1690210809000},"page":"757-762","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["The Influence of Long-Acting Somatostatin Analogs on 68Ga-DOTATATE Uptake in Patients With Neuroendocrine Tumors"],"prefix":"10.1097","volume":"48","author":[{"given":"Youssef","family":"Chahid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khaled","family":"Hashimi","sequence":"additional","affiliation":[{"name":"Radiology and Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewoudt M.W.","family":"van de Garde","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Utrecht University, Utrecht"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heinz-Josef","family":"Kl\u00fcmpen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Amsterdam UMC, University of Amsterdam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. Harry","family":"Hendrikse","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Booij","sequence":"additional","affiliation":[{"name":"Radiology and Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hein J.","family":"Verberne","sequence":"additional","affiliation":[{"name":"Radiology and Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,7,22]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","year":"2017","journal-title":"JAMA Oncol"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1159\/000179899","article-title":"Expression of somatostatin and dopamine 2 receptors in neuroendocrine tumours and the potential role for new biotherapies","volume":"89","year":"2009","journal-title":"Neuroendocrinology"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.3390\/ijms20123049","article-title":"Somatostatin analogues in the treatment of neuroendocrine tumors: past, present and future","volume":"20","year":"2019","journal-title":"Int J Mol Sci"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1007\/s00259-010-1512-3","article-title":"Procedure guidelines for PET\/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE","volume":"37","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","year":"2017","journal-title":"N Engl J Med"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1200\/JCO.2018.78.5865","article-title":"Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with (177)Lu-Dotatate in the phase III NETTER-1 trial","volume":"36","year":"2018","journal-title":"J Clin Oncol"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11307-014-0795-3","article-title":"SUV of [68Ga]DOTATOC-PET\/CT predicts response probability of PRRT in neuroendocrine tumors","volume":"17","year":"2015","journal-title":"Mol Imaging Biol"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13550-020-00651-z","article-title":"Tumour-to-liver ratio determined by [(68)Ga]Ga-DOTA-TOC PET\/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours","volume":"10","year":"2020","journal-title":"EJNMMI Res"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000225946","article-title":"ENETS consensus guidelines for the standards of care in neuroendocrine tumors: somatostatin receptor imaging with (111)in-pentetreotide","volume":"90","year":"2009","journal-title":"Neuroendocrinology"},{"key":"bib13-20250621","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1007\/s00259-017-3728-y","article-title":"Guideline for PET\/CT imaging of neuroendocrine neoplasms with (68)Ga-DOTA-conjugated somatostatin receptor targeting peptides and (18)F-DOPA","volume":"44","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib14-20250621","doi-asserted-by":"crossref","first-page":"204","DOI":"10.2967\/jnumed.122.264860","article-title":"SNMMI procedure standard\/EANM practice guideline for SSTR PET: imaging neuroendocrine tumors","volume":"64","year":"2023","journal-title":"J Nucl Med"},{"key":"bib15-20250621","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/RLU.0000000000004670","article-title":"Impact of cold somatostatin analog administration on somatostatin receptor imaging: a systematic review","volume":"48","year":"2023","journal-title":"Clin Nucl Med"},{"key":"bib16-20250621","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2967\/jnumed.117.192203","article-title":"Long-acting somatostatin analog therapy differentially alters 68Ga-DOTATATE uptake in normal tissues compared with primary tumors and metastatic lesions","volume":"59","year":"2018","journal-title":"J Nucl Med"},{"key":"bib17-20250621","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.2967\/jnumed.119.226332","article-title":"A prospective observational study to evaluate the effects of long-acting somatostatin analogs on (68)Ga-DOTATATE uptake in patients with neuroendocrine tumors","volume":"60","year":"2019","journal-title":"J Nucl Med"},{"key":"bib18-20250621","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.2967\/jnumed.111.089276","article-title":"Treatment with octreotide does not reduce tumor uptake of (68)Ga-DOTATATE as measured by PET\/CT in patients with neuroendocrine tumors","volume":"52","year":"2011","journal-title":"J Nucl Med"},{"key":"bib19-20250621","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1007\/s00259-018-4117-x","article-title":"Influence of lanreotide on uptake of 68Ga-DOTATATE in patients with neuroendocrine tumours: a prospective intra-patient evaluation","volume":"46","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib20-20250621","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40644-018-0136-x","article-title":"Changes in biodistribution on (68)Ga-DOTA-Octreotate PET\/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogression","volume":"18","year":"2018","journal-title":"Cancer Imaging"},{"key":"bib21-20250621","first-page":"3652","article-title":"Differential regulation of somatostatin receptor type 2 (SST 2) expression in AR4-2J tumor cells implanted into mice during octreotide treatment","volume":"59","year":"1999","journal-title":"Cancer Res"},{"key":"bib22-20250621","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000367850","article-title":"The status of neuroendocrine tumor imaging: from darkness to light?","volume":"101","year":"2015","journal-title":"Neuroendocrinology"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004776","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T19:04:50Z","timestamp":1750532690000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,22]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000004776","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,22]]}}}